Program
vustanaciclib
Also written as “RGT-419B”, “GDC-4198” and “RGT-419B in combination with hormonal therapy”.
Its studies are mostly in Breast Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regor Pharmaceuticals | 22 open or running | phase 1since Feb 24, 2022 | Feb 24, 2022 | Dec 30, 2026phase 1 · NCT06299124 |
| Hoffmann-La Roche | 11 open or running | phase 2since Jul 31, 2025 | Jul 31, 2025 | Aug 31, 2028phase 2 · NCT07100106 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6794 vustanaciclib
, phase 2, as of Oct 22, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2022First study: phase 1 study in Breast NeoplasmsNew to Regor PharmaceuticalsRegor Pharmaceuticals · NCT05304962 · 64 planned · United States
- Mar 1, 2024Phase 1 study in Breast NeoplasmsRegor Pharmaceuticals · NCT06299124 · 40 enrolled · China
- Jul 31, 2025Hoffmann-La Roche's first study: phase 2 study in Breast NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT07100106 · 285 planned · United States, Australia, Brazil and more
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Breast NeoplasmsRegor Pharmaceuticals · NCT06299124
- Dec 30, 2026Primary completion: phase 1 study in Breast NeoplasmsRegor Pharmaceuticals · NCT05304962
- Aug 31, 2028Primary completion: phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT07100106
TargetBeta
“An orally bioavailable third-generation inhibitor of cyclin-dependent kinase (CDK) types 2 (CDK2), 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, vustanaciclib selectively targets and inhibits CDK2, CDK4 and CDK6, which inhibits the phosphorylation of ret…”NCIt, read by Claude
“An orally bioavailable third-generation inhibitor of cyclin-dependent kinase (CDK) types 2 (CDK2), 4 (CDK4) and 6 (CDK6), ”NCIt, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07100106Breast Neoplasms · United States, Australia, Brazil and more | 2 | Recruiting | Hoffmann-La Roche | Aug 31, 2028 | 285 |
| NCT06299124Breast Neoplasms · China | 1 | Active, not recruiting | Regor Pharmaceuticals | Dec 30, 2026 | 40 |
| NCT05304962Breast Neoplasms · United States | 1 | Recruiting | Regor Pharmaceuticals | Dec 30, 2026 | 64 |
How it is read
Names in the registry
- “RGT-419B”, 2 entries
- “GDC-4198”, 1 entry
- “RGT-419B in combination with hormonal therapy”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.